1. Pink Sheet
  2. >>Compliance

Could Virtual Tools Help US FDA Eliminate Inspection Backlog?

 
• By Derrick Gingery

A former CDER compliance office director suggested the agency initiate virtual visits at low-risk facilities to help catch up on manufacturing facility surveillance inspections.

document review
Three to five RRAs, which involve document reviews, could be conducted in the same time as one inspection, Donald Ashley said. • Source: Shutterstock

Increasing virtual inspections may help the US Food and Drug Administration reduce its surveillance inspection backlog, but public health needs could complicate such a plan.

During the height of the COVID-19 pandemic, most international travel was restricted or not feasible, meaning many routine inspections of drug manufacturing facilities were postponed. The result was a substantial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

More from Pink Sheet

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By Vibha Sharma

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A

 
• By Neena Brizmohun

Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.

Europe’s UPC Issues Landmark Ruling On Second Medical Use Claims

 
• By Neena Brizmohun

The verdict by the Unified Patent Court in the dispute between Sanofi/Regeneron Pharmaceuticals and Amgen explains what companies should look out for when deciding whether infringement has taken place when it comes to second medical use patents.